1. Home
  2. STRA vs RAPP Comparison

STRA vs RAPP Comparison

Compare STRA & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Strategic Education Inc.

STRA

Strategic Education Inc.

HOLD

Current Price

$83.77

Market Cap

1.7B

Sector

Real Estate

ML Signal

HOLD

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$41.93

Market Cap

1.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
STRA
RAPP
Founded
2017
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
1996
2024

Fundamental Metrics

Financial Performance
Metric
STRA
RAPP
Price
$83.77
$41.93
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$87.00
$48.50
AVG Volume (30 Days)
268.6K
431.1K
Earning Date
04-23-2026
05-08-2026
Dividend Yield
3.04%
N/A
EPS Growth
15.85
24.34
EPS
1.48
N/A
Revenue
$997,137,000.00
N/A
Revenue This Year
$4.71
N/A
Revenue Next Year
$4.67
N/A
P/E Ratio
$57.93
N/A
Revenue Growth
57.23
N/A
52 Week Low
$69.70
$13.64
52 Week High
$87.38
$43.76

Technical Indicators

Market Signals
Indicator
STRA
RAPP
Relative Strength Index (RSI) 60.26 59.76
Support Level $78.66 $33.54
Resistance Level $85.86 $43.76
Average True Range (ATR) 2.12 2.88
MACD 0.73 0.15
Stochastic Oscillator 76.97 66.30

Price Performance

Historical Comparison
STRA
RAPP

About STRA Strategic Education Inc.

Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: